<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00949546</url>
  </required_header>
  <id_info>
    <org_study_id>20031168</org_study_id>
    <nct_id>NCT00949546</nct_id>
  </id_info>
  <brief_title>Treatment of Hidradenitis Suppurativa Using Etanercept</brief_title>
  <official_title>Treatment of Hidradenitis Suppirativa With Etanercept Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapy with etanercept, a TNF inhibitor will reverse the inflammation, symptoms and quality
      of life and allow healing of HS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Physician global assessment of HS of clear or mild at week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>placebo controlled</arm_group_label>
    <description>A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>etanercept 50 mg sc twice weekly</description>
    <arm_group_label>placebo controlled</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic HS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HS for &gt; 6months defined as tender and/or painful, red nodules and/or plaques
             (confluent nodules) with or without scarring, foul odor, or draining sinuses
             clinically with HS

          -  Localizes to skin folds including any of axillx, breast, abdomen and groin

          -  active disease

          -  Negative pregnancy test within 7 days before the first dose of study drug

          -  Sexually active subjects of childbearing potential must agree to use medically
             acceptable form of contraception during screening and throughout the study

        Exclusion Criteria:

          -  Concurrent active infection including tuberculosis

          -  Concurrent therapy or therapy 30 days prior with systemic corticosteroids, systemic
             immunosuppressants, systemic retinoids or ant-TNF agents

          -  Severe comorbidities (diabetes mellitus requiring insulin, Q F of any severity, MI,
             unstable angina eectoris, uncontrolled hypertension, oxygendependent severe pulmonary
             disease, history of cancer *thin 5_ years except cutaneous basal cell or squamous cell
             carcinoma or in situ cervical carcinoma, history of TB or TB exposure, chronic
             hepatitis B or C, SLE, history of multiple sclerosis, transverse myelitis, optic
             neuritis or epilepsy

          -  Currently enrolled or enrolled within 90 days prior in any trial for treatment of HS

          -  Known HIV positive

          -  Contraindication to etanercept as defined in package insert
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Adams, MD, Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2009</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

